Interferon-alpha
Title: Interferon-a
Additional Names: Alfa-interferon; alpha-interferon; IFN-a; LeIF; leukocyte interferon; lymphoblastoid interferon
Literature References: Cytokine with antiviral, antiproliferative, and immunomodulatory activity. Produced by leukocytes stimulated by virus, bacteria, or protozoa as part of the immune response; artificially induced by double-stranded RNA. Inhibits protein synthesis and viral replication; enhances cytotoxic activity. Multiple subtypes have been identified which contain ~166 amino acids and are variably glycosylated; mol wt 16-27.5 kDa. Identification of interferon produced by human leukocytes exposed to virus: I. Gresser, Proc. Soc. Exp. Biol. Med. 108, 799 (1961). Purification and characterization: M. Rubinstein et al., Proc. Natl. Acad. Sci. USA 76, 640 (1979). Prepn by recombinant DNA technology: S. Nagata et al., Nature 284, 316 (1980); D. V. Goeddel et al., ibid. 287, 411 (1980). Comparison of structures and activities of HuIFN-a subtypes: M. Streuli et al., Science 209, 1343 (1980); D. V. Goeddel et al., Nature 290, 20 (1981). Review: A. Meager in Cytokines, A. R. Mire-Sluis, R. Thorpe, Eds. (Academic Press, San Diego, 1998) pp 361-389. Review of pharmacology and clinical efficacy in malignant and viral disease: R. T. Dorr, Drugs 45, 177-211 (1993); in chronic viral hepatitis: M. H. Woo, T. G. Burnakis, Ann. Pharmacother. 31, 330-337 (1997); of use in metastatic renal cell carcinoma: A. Ravaud, M.-S. Dilhuydy, Expert Opin. Biol. Ther. 5, 749-762 (2005).
 
Derivative Type: Interferon alfa-2a
CAS Registry Number: 77907-69-8
CAS Name: Interferon-aA (human leukocyte protein moiety)
Additional Names: IFN-aA
Manufacturers' Codes: Ro-22-8181
Trademarks: Canferon (Takeda); Laroféron (Roche); Roferon-A (Roche)
Literature References: Recombinant HuIFN-a produced in E. coli. Contains 165 amino acids; mol wt ~19 kDa. Symposium on clinical antineoplastic activity: Semin. Oncol. 12, Suppl. 5, 1-34 (1985). Review of clinical efficacy in hepatitis C: C. M. Perry, M. I. Wilde, BioDrugs 10, 65-89 (1998).
 
Derivative Type: Interferon alfa-2b
CAS Registry Number: 98530-12-2
CAS Name: Interferon a2 (human leukocyte clone pM21 protein moiety reduced)
Additional Names: interferon a2 (human leukocyte clone Hif-SN206 protein moiety reduced); IFN-a2
Manufacturers' Codes: Sch-30500; YM-14090
Trademarks: Introna (Schering-Plough); Intron A (Schering-Plough); Viraferon (Schering-Plough)
Literature References: Recombinant HuIFN-a produced in E. coli. Mol wt ~19 kDa. Symposium on clinical antineoplastic activity: Invest. New Drugs 5, Suppl, S1-S77 (1987). Clinical trial in hepatitis C: S. Schenker et al., J. Interferon Cytokine Res. 17, 665 (1997).
 
Derivative Type: Interferon alfa-2c
CAS Registry Number: 142192-09-4
CAS Name: Interferon a2 (human clone pAD19B-IFN protein moiety reduced)
Trademarks: Berofor (Boehringer, Ing.)
Literature References: Clinical trial in chronic myelogenous leukemia: J. Thaler et al., Leuk. Res. 21, 75 (1997); in lung cancer: C. Prior et al., Eur. Respir. J. 10, 392 (1997).
 
Derivative Type: Interferon alfacon-1
CAS Registry Number: 118390-30-0
CAS Name: N-L-Methionyl-22-L-arginine-76-L-alanine-78-L-aspartic acid-79-L-glutamic acid-86-L-tyrosine-90-L-tyrosine-156-L-threonine-157-L-asparagine-158-L-leucine-interferon a1 (human lymphoblast reduced)
Additional Names: consesus interferon; CIFN
Trademarks: Infergen (Amgen)
Literature References: Synthetic, recombinant interferon derived by assigning the most commonly observed amino acid in each position of several alpha IFN subtypes to create a consensus sequence. Contains 166 amino acids; mol wt 19.5 kDa. Molecular characterization and bioactivity: L. M. Blatt et al., J. Interferon Cytokine Res. 16, 489 (1996). Clinical trial in hepatitis C: M. J. Tong et al., Hepatology 26, 747 (1997).
 
Derivative Type: Interferon alfa-n1
Manufacturers' Codes: NSC-339140
Trademarks: Sumiferon (Sumitomo); Wellferon (Glaxo Wellcome)
Literature References: Mixture of natural human a-interferons derived from lymphoblastoid cells exposed to Sendai virus. Review of clinical trials in hepatitis C: G. C. Farrell, Hepatology 26, Suppl. 1, 96S-100S (1997); of pharmacology and clinical efficacy: C. M. Perry, A. J. Wagstaff, BioDrugs 9, 125-154 (1998).
 
Derivative Type: Interferon alfa-n3
Trademarks: Alferon (Interferon Sciences)
Literature References: Mixture of natural, human a-interferons produced by human leukocytes exposed to Sendai virus. mol wt 16-27 kDa. Clinical trial in hepatitis C: D. M. Simon et al., Hepatology 25, 445 (1997).
 
Therap-Cat: Antiviral; antineoplastic.
Keywords: Antineoplastic; Immunomodulators; Antiviral.

Others monographs:
n-Octyl-β-D-glucosideTsuduranineCarzenideZinc p-Phenolsulfonate
Succinanilic AcidIsobutyric AcidSchiff BasesCarubicin
ChlorsulfuronCroceic AcidCopper(I) Thiophene-2-carboxylatep-Aminoacetanilide
Barium CyanideTropacocaineTirapazamineAtenolol
©2016 DrugLead US FDA&EMEA